Literature DB >> 16920886

CFTR inhibition mimics the cystic fibrosis inflammatory profile.

Aura Perez1, Amanda C Issler, Calvin U Cotton, Thomas J Kelley, Alan S Verkman, Pamela B Davis.   

Abstract

Primary airway epithelial cells grown in air-liquid interface differentiate into cultures that resemble native epithelium morphologically, express ion transport similar to those in vivo, and secrete cytokines in response to stimuli. Comparisons of cultures derived from normal and cystic fibrosis (CF) individuals are difficult to interpret due to genetic differences besides CFTR. The recently discovered CFTR inhibitor, CFTR(inh)-172, was used to create a CF model with its own control to test if loss of CFTR-Cl(-) conductance alone was sufficient to initiate the CF inflammatory response. Continuous inhibition of CFTR-Cl(-) conductance for 3-5 days resulted in significant increase in IL-8 secretion at basal (P = 0.006) and in response to 10(9) Pseudomonas (P = 0.0001), a fourfold decrease in Smad3 expression (P = 0.02), a threefold increase in RhoA expression, and increased NF-kappaB nuclear translocation upon TNF-alpha/IL-1beta stimulation (P < 0.000001). CFTR inhibition by CFTR(inh)-172 over this period does not increase epithelial sodium channel activity, so lack of Cl(-) conductance alone can mimic the inflammatory CF phenotype. CFTR(inh)-172 does not affect IL-8, IL-6, or granulocyte/macrophage colony-stimulating factor secretion in two CF phenotype immortalized cell lines: 9/HTEo(-) pCEP-R and 16HBE14o(-) AS, or IL-8 secretion in primary CF cells, and inhibitor withdrawal abolishes the increased response, so CFTR(inh)-172 effects on cytokines are not direct. Five-day treatment with CFTR(inh)-172 does not affect cells deleteriously as evidenced by lactate dehydrogenase, trypan blue, ciliary activity, electron micrograph histology, and inhibition reversibility. Our results support the hypothesis that lack of CFTR activity is responsible for the onset of the inflammatory cascade in the CF lung.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920886     DOI: 10.1152/ajplung.00403.2005

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  71 in total

1.  Pediatric Respiratory Assembly. Mini symposium on lung inflammation.

Authors:  Larry C Lands; A Keith Tanswell; Sophie Laberge; Christine McCusker; Felix Ratjen
Journal:  Can Respir J       Date:  2010 Mar-Apr       Impact factor: 2.409

Review 2.  Genetic variation and clinical heterogeneity in cystic fibrosis.

Authors:  Mitchell L Drumm; Assem G Ziady; Pamela B Davis
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

3.  Control the platelets, control the disease: A novel cystic fibrosis hypothesis.

Authors:  Siobhan Branfield; A Valance Washington
Journal:  J Thromb Haemost       Date:  2020-05-28       Impact factor: 5.824

4.  A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy.

Authors:  Kerstin Pohl; Elaine Hayes; Joanne Keenan; Michael Henry; Paula Meleady; Kevin Molloy; Bakr Jundi; David A Bergin; Cormac McCarthy; Oliver J McElvaney; Michelle M White; Martin Clynes; Emer P Reeves; Noel G McElvaney
Journal:  Blood       Date:  2014-06-16       Impact factor: 22.113

5.  Eicosanoid release is increased by membrane destabilization and CFTR inhibition in Calu-3 cells.

Authors:  Florence Borot; Diane-Lore Vieu; Grazyna Faure; Janine Fritsch; Julien Colas; Sandra Moriceau; Maryvonne Baudouin-Legros; Franck Brouillard; Jesus Ayala-Sanmartin; Lhousseine Touqui; Marc Chanson; Aleksander Edelman; Mario Ollero
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

6.  A cation counterflux supports lysosomal acidification.

Authors:  Benjamin E Steinberg; Kassidy K Huynh; Alexandre Brodovitch; Sabrina Jabs; Tobias Stauber; Thomas J Jentsch; Sergio Grinstein
Journal:  J Cell Biol       Date:  2010-06-21       Impact factor: 10.539

7.  Increased plasma membrane cholesterol in cystic fibrosis cells correlates with CFTR genotype and depends on de novo cholesterol synthesis.

Authors:  Danjun Fang; Richard H West; Mary E Manson; Jennifer Ruddy; Dechen Jiang; Stephen F Previs; Nitin D Sonawane; James D Burgess; Thomas J Kelley
Journal:  Respir Res       Date:  2010-05-20

8.  Proinflammatory phenotype and increased caveolin-1 in alveolar macrophages with silenced CFTR mRNA.

Authors:  Yaqin Xu; Anja Krause; Hiroko Hamai; Ben-Gary Harvey; Tilla S Worgall; Stefan Worgall
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

9.  Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum.

Authors:  David J Serisier; Mary P Carroll; Janis K Shute; Simon A Young
Journal:  Respir Res       Date:  2009-07-06

10.  Lack of CFTR in skeletal muscle predisposes to muscle wasting and diaphragm muscle pump failure in cystic fibrosis mice.

Authors:  Maziar Divangahi; Haouaria Balghi; Gawiyou Danialou; Alain S Comtois; Alexandre Demoule; Sheila Ernest; Christina Haston; Renaud Robert; John W Hanrahan; Danuta Radzioch; Basil J Petrof
Journal:  PLoS Genet       Date:  2009-07-31       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.